GlassScriptPhysician profile
Amanda S Thomas
NPI 1346687423
$9,202.88
in general payments reported to CMS, 2019-2025
42 companies · $927 in 2025
The $927 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,248 · 2022: $2,533 · 2023: $2,356 · 2024: $2,139 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,261 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,261.45 |
| Education | $161.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,060.87 | 2021-2025 | Jardiance, Mounjaro, Trulicity |
| Abbott Laboratories | $744.84 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $723.37 | 2021-2025 | |
| Dexcom, INC. | $698.63 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Novo Nordisk INC | $667.75 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $620.97 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $589.46 | 2021-2023 | Farxiga |
| Amgen INC. | $502.44 | 2021-2025 | Repatha, Tepezza, Tavneos |
| Sanofi-Aventis U.S. LLC | $444.20 | 2021-2024 | |
| Radius Health, INC. | $436.74 | 2021-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.05 | 2021-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $337.31 | 2021-2024 | Gvoke Hypopen, Recorlev, Keveyis |
| Opko Pharmaceuticals, LLC | $221.46 | 2021-2024 | Rayaldee |
| Fresenius USA Marketing, INC. | $181.74 | 2021-2024 | Velphoro |
| Insulet Corporation | $173.14 | 2021-2025 | Omnipod |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $146.39 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $112.06 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $111.77 | 2023-2025 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $108.85 | 2021-2023 | Verquvo, Steglatro, Steglujan |
| Corcept Therapeutics | $97.90 | 2024 | Korlym |
| Daiichi Sankyo INC. | $92.68 | 2021-2022 | |
| Medtronic, INC. | $89.30 | 2024-2025 | Intellis Adaptivestim, Minimed 780g |
| Vifor Pharma, INC. | $86.63 | 2021-2024 | |
| Travere Therapeutics, INC. | $85.80 | 2023 | |
| Abbvie INC. | $66.99 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $61.07 | 2024 | Acthar |
| Calliditas Therapeutics US INC. | $54.41 | 2024 | |
| Aurinia Pharma U.S., INC. | $49.09 | 2023 | Lupkynis |
| Amarin Pharma, INC. | $39.65 | 2021 | |
| Esperion Therapeutics, INC. | $37.58 | 2024-2025 | Nexletol |
| Stryker Corporation | $27.67 | 2025 | Pangea |
| Vertex Pharmaceuticals Incorporated | $27.52 | 2025 | |
| Sumitomo Pharma America, INC. | $24.87 | 2025 | Gemtesa |
| Averitas Pharma INC. | $21.40 | 2024 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $18.52 | 2024 | Jynarque |
| Becton, Dickinson and Company | $16.60 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.12 | 2021 | |
| Pfizer INC. | $15.68 | 2025 | |
| Astellas Pharma US INC | $12.44 | 2021 | |
| Horizon Therapeutics Plc | $11.74 | 2021 | |
| Phathom Pharmaceuticals, INC. | $11.18 | 2025 | Voquezna |
| Beta Bionics, INC. | $10.00 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.